The Biochemistry and Biotechnology Facility (BBF) makes available to Fox Chase Cancer Center (FCCC) investigators a group of state-of-the-art technologies for the identification, characterization, and utilization of genes, polymorphisms, transcripts, proteins;and peptides. The four components of BBF are all important and synergistic. DMA Synthesis delivers error-free oligonucleotides, regular, modified, or fluorescent probes, overnight with full quality control, Quantitative Real-time PCR provides high sensitivity and accuracy gene expression quantitation and distinguishes regulation by alternate transcripts. Mass Spectrometry identifies the components of protein complexes and supports biochemical, biophysical, and drug research. Proteomics reveals the global protein changes and modifications in response to disease states or drug treatments and discovers secondary targets of cancer-causing mutations. Anthony T. Yeung, Ph.D., (Biomolecular Structure and Function) directs BBF to provide uniformly high quality products at the cutting edge of performance. This is accomplished by proactive user interactions, and external collaborations with the leaders in each discipline. The Facility is used by 53 peer-reviewed investigators with 130 grants involving all three FCCC Divisions. About 95% of its use is by investigators with peer-reviewed funding. During the last grant period, demands on DNA synthesis (700 oligonucleotides per month by 2003) and Mass Spectrometry (about 22 projects in 2003) have both doubled. In addition, new services of Quantitative Real-time PCR and Proteomics have been developed in BBF because they are critical technologies for cancer research and are used by 13 and 7 investigators, respectively. In 2003, DNA Synthesis has contributed to 48 peer-reviewed, funded investigators, Quantitative Real-time PCR, 14;Mass Spectrometry, 23;and Proteomics, 7. BBF personnel have in-depth understanding of the science of the users and facilitate their research as highly integrated tools and participants of these research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-47
Application #
7881777
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
47
Fiscal Year
2009
Total Cost
$586,248
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Auerbach, M V; Heckman, C J; Darlow, S (2018) To protect or not to protect: examining reasons for sun protection among young women at risk for skin cancer. J Behav Med 41:528-536
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886

Showing the most recent 10 out of 1280 publications